Please select the eligibility criteria that correspond to the clinical trial below.
Title: Interest of Pulsatile Perfusion Preservation on Outcomes in Kidney Transplantation From Expanded Criteria Donors
Brief Summary: Our hypothesis is that the Waters Medical® pulsatile perfusion machine (RM 3) is a way to improve delayed graft function (DGF) in marginal grafts, and some perfusion profiles (flow, pressure, resistance index, venous effluent pH) are correlated with better recovery of renal function (without dialysis during the first week after transplant).

Observation or Investigation Method Used :

The study is multicenter, prospective, open, controlled and randomized:grafts are divided into two parallel groups:

* group 1 corresponds to a conservation of grafts in static incubation
* group 2 corresponds to conservation using a pulsatile perfusion machine

Duration and Organizational Arrangements for Research :

The total duration of the study is planned for 36 months. This duration includes:

* an inclusion period that will last 24 months,
* the follow-up of recipient patients from the day of transplantation until twelve months after the operation


Options:
A: Inclusion Criteria for marginal graft:

* donors over 60 years of age
* donors between 50 and 60 years of age with at least one of the following characteristics :

  * history of diabetes mellitus
  * history of high blood pressure
  * serum creatinine \>1,5 mg/dL
  * death by stroke (haemorrhagic or thrombotic)

Inclusion criteria for recipient :

* patients registered on the kidney transplant waiting list likely to receive a marginal kidney
* immunized patients whose anti-HLA antibody specificities have been determined

Exclusion Criteria for recipient:

* pregnant or breastfeeding women
* people who have been incarcerated
* minors
* adults under guardianship
* people who are not affiliated with the French healthcare system
* people with HLA immunization whose HLA antibody specificities have not been determined
B: Inclusion Criteria:

* Donor

  1. Comply with the national DCD（donor after citizen death) guideline
  2. No high risk activities: such as history of drug abuse, history of intravenous drug use and risky sexual behavior
  3. No malignant melanoma, metastatic cancer, or incurable cancer; some of the early stages of cancer after a successful treatment can also be considered
  4. No active, untreated systemic bacterial, viral or fungal infection;
  5. Patients definitely identified
  6. Mechanical perfusion RI (resistance index ) \[0.18, 0.50\]

Recipient:

1. Age\> = 16 years old, male or female
2. BMI\<28
3. First Renal transplantation
4. Not in pregnancy or lactation, pregnancy test was negative, and promise not to be pregnant during treatment.
5. Before the clinical trial, Patient sign informed consent voluntarily

Exclusion Criteria:

* Donor

  1. Older than 50 years old
  2. Serum HBV (hepatitis B virus), HCV (hepatitis C virus), HIV positive
  3. Donor kidney cold storage time over 30 hours
  4. Warm ischemia time over 20 minutes
  5. Other reagents are added perfusion for regulation of donor renal function

Recipient:

1. Double organ or multi-organ transplant
2. Blood type-incompatible
3. Patients with other malignant diseases
C: Inclusion Criteria:

* kidney-only transplant
* renal replacement therapy at time of transplant
* receiving standard immunosuppression regimen post-transplant.
* Donation after circulatory death (DCD) Maastricht type III, IV, or V or extended criteria donation after brain death (DBD) donor kidneys.

Exclusion Criteria:

* pre-emptive at time of transplant
* receive a multi-organ or dual kidney transplant
* age donor or recipient below 18 years
* Maastricht type I and II DCD
* donor kidneys preserved on static cold storage (SCS)
* kidneys retrieved after normothermic regional perfusion (NRP)
* Recipient virtual panel reactive antibodies ≥85%
* Recipient for who it is agreed in advance that dialysis after transplant is required, such as in the context of hyperoxaluria
D: Inclusion Criteria:

* \> 18 years of age,
* Brain dead organ donor,
* Authorization for research

Exclusion Criteria:

* Donation after Cardiac Death (DCD) Donor
* Coagulopathy, Hemodynamic instability, Electrolyte deficiencies, Pre-existing kidney disease (per study protocol)

Answer: A